Vyne Therapeutics Inc
VYNE0.355USD
+0.002+0.62%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
5.67MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Vyne Therapeutics Inc Unternehmen
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Unternehmensinformationen
BörsenkürzelVYNE
Name des UnternehmensVyne Therapeutics Inc
IPO-datumJan 25, 2018
CEOMr. David Domzalski
Anzahl der mitarbeiter13
WertpapierartOrdinary Share
GeschäftsjahresendeJan 25
Addresse685 Route 202/206 N., Suite 301
StadtBRIDGEWATER
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl08807
Telefon18007757936
Websitehttps://vynetherapeutics.com/
BörsenkürzelVYNE
IPO-datumJan 25, 2018
CEOMr. David Domzalski
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
116.19K
-2.86%
Mr. Patrick G. Lepore
Mr. Patrick G. Lepore
Lead Independent Director
Lead Independent Director
51.47K
--
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
42.30K
-5.45%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Mr. Anthony Bruno
Mr. Anthony Bruno
Independent Director
Independent Director
--
--
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Sharon Barbari
Ms. Sharon Barbari
Independent Director
Independent Director
--
--
Dr. Christine Borowski, Ph.D.
Dr. Christine Borowski, Ph.D.
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
116.19K
-2.86%
Mr. Patrick G. Lepore
Mr. Patrick G. Lepore
Lead Independent Director
Lead Independent Director
51.47K
--
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
42.30K
-5.45%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Mr. Anthony Bruno
Mr. Anthony Bruno
Independent Director
Independent Director
--
--
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Royalty revenues
501.00K
0.00%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Royalty revenues
501.00K
0.00%
Aktionärsstatistik
Aktualisiert: Sun, Jun 1
Aktualisiert: Sun, Jun 1
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Eventide Asset Management, LLC
8.37%
Access Industries, Inc.
6.70%
Citadel Advisors LLC
6.60%
Acorn Capital Advisors, LLC
4.72%
Delaware Street Capital, L.L.C.
4.18%
Other
69.43%
Aktionäre
Aktionäre
Anteil
Eventide Asset Management, LLC
8.37%
Access Industries, Inc.
6.70%
Citadel Advisors LLC
6.60%
Acorn Capital Advisors, LLC
4.72%
Delaware Street Capital, L.L.C.
4.18%
Other
69.43%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
26.69%
Investment Advisor
17.90%
Corporation
6.70%
Individual Investor
2.22%
Private Equity
1.54%
Investment Advisor/Hedge Fund
1.05%
Research Firm
0.32%
Venture Capital
0.20%
Other
43.37%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
83
9.44M
56.62%
-1.32M
2025Q1
81
9.36M
56.20%
-1.38M
2024Q4
92
9.37M
63.49%
-533.87K
2024Q3
88
8.98M
61.30%
-594.32K
2024Q2
89
9.65M
66.73%
+287.65K
2024Q1
92
9.64M
67.66%
+101.95K
2023Q4
101
10.22M
72.71%
+4.63M
2023Q3
117
471.27K
14.37%
-340.06K
2023Q2
135
501.83K
15.37%
-314.68K
2023Q1
168
461.83K
16.95%
-412.21K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Eventide Asset Management, LLC
1.39M
8.37%
--
--
Mar 31, 2025
Access Industries, Inc.
1.12M
6.7%
--
--
Feb 14, 2025
Citadel Advisors LLC
1.10M
6.6%
-130.13K
-10.58%
Mar 31, 2025
Acorn Capital Advisors, LLC
785.94K
4.72%
+328.97K
+71.99%
Mar 31, 2025
Delaware Street Capital, L.L.C.
696.47K
4.18%
--
--
Sep 30, 2024
Dafna Capital Management, LLC
636.10K
3.82%
+636.10K
--
Mar 31, 2025
The Vanguard Group, Inc.
475.65K
2.85%
+521.00
+0.11%
Mar 31, 2025
Exome Asset Management LLC
462.80K
2.78%
+109.37K
+30.94%
Mar 31, 2025
Palo Alto Investors LP
445.43K
2.67%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
344.13K
2.06%
+190.00K
+123.27%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Feb 10, 2023
Merger
18<1
Feb 10, 2023
Merger
18<1
Feb 10, 2023
Merger
18<1
Feb 10, 2023
Merger
18<1
Feb 12, 2021
Merger
4<1
Feb 12, 2021
Merger
4<1
Datum
Art
Verhältnis
Feb 10, 2023
Merger
18<1
Feb 10, 2023
Merger
18<1
Feb 10, 2023
Merger
18<1
Feb 10, 2023
Merger
18<1
Feb 12, 2021
Merger
4<1
Feb 12, 2021
Merger
4<1
Feb 12, 2021
Merger
4<1
Feb 12, 2021
Merger
4<1
